Program
Diazepam
Also written as “diazepam nasal spray”, “NRL-1” and “Diazepam Nasal Spray [Valtoco]”.
Its studies are mostly in Epilepsy · Seizures · Drug Resistant Epilepsy, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Acorda Therapeutics | 40 open or running | phase 2since Aug 12, 2011 | Aug 12, 2011 | none ahead |
| Neurelis | 30 open or running | phase 3since Mar 17, 2016 | Mar 17, 2016 | none ahead |
| Pfizer | 10 open or running | phase 3since Apr 27, 2006 | Apr 27, 2006 | none ahead |
| UCB | 10 open or running | phase 1since Jun 5, 2025 | Jun 5, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 27, 2006First study: phase 3 study in SeizuresNew to PfizerPfizer · NCT00319501 · 234 enrolled · United States
- Aug 12, 2011Acorda Therapeutics's first study: phase 2 study in EpilepsyNew to Acorda TherapeuticsAcorda Therapeutics · NCT01417078 · 31 enrolled · United States
- Dec 9, 2014Phase 2 study in EpilepsyAcorda Therapeutics · NCT02316847 · 126 enrolled · United States
- Jun 15, 2015Phase 2 study in Drug Resistant EpilepsyAcorda Therapeutics · NCT02474407 · 78 enrolled · United States
- Jan 22, 2016Phase 1 study in HealthyAcorda Therapeutics · NCT02663999 · 15 enrolled · United States
- Mar 17, 2016Neurelis's first study: phase 1 study in EpilepsyNew to NeurelisNeurelis · NCT02724423 · 57 enrolled · United States
- Mar 17, 2016Phase 3 study in SeizuresNeurelis · NCT02721069 · 175 enrolled · United States
- Sep 15, 2021Phase 2 study in EpilepsyNeurelis · NCT05076838 · 36 enrolled · United States
- Jun 5, 2025UCB's first study: phase 1 study in Healthy ParticipantsNew to UCBUCB · NCT07020988 · 55 enrolled · United States
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Pfizer | phase 4 | 96 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| Alprazolamrule | Viatris | phase 4 | 35 |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 14 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07020988Healthy Participants · United States | 1 | Completed | UCB | Jan 6, 2026 | 55 |
| NCT05076838Epilepsy · United States | 2 | Completed | Neurelis | Mar 11, 2025 | 36 |
| NCT02724423Epilepsy · United States | 1 | Completed | Neurelis | Apr 10, 2019 | 57 |
| NCT02721069Seizures · United States | 3 | Completed | Neurelis | Jun 17, 2020 | 175 |
| NCT02663999Healthy · United States | 1 | Completed | Acorda Therapeutics | Apr 2016 | 15 |
| NCT02474407Drug Resistant Epilepsy · United States | 2 | Terminated | Acorda Therapeutics | May 2016 | 78 |
| NCT02316847Epilepsy · United States | 2 | Terminated | Acorda Therapeutics | Jul 2016 | 126 |
| NCT01417078Epilepsy · United States | 2 | Completed | Acorda Therapeutics | Feb 2013 | 31 |
| NCT00319501Seizures · United States | 3 | Completed | Pfizer | Jul 2014 | 234 |
How it is read
Names in the registry
- “diazepam nasal spray”, 3 entries
- “Diazepam”, 2 entries
- “NRL-1”, 2 entries
- “Diazepam Nasal Spray [Valtoco]”, 1 entry
- “Vanquix Auto-Injector (Diazepam Injection)”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 4 studies
- Seizures, 2 studies
- Drug Resistant Epilepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.